Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans

Andreas Puschnik1, Louis Lau1,9, Elizabeth A. Cromwell2,9, Angel Balmaseda3, Simona Zompi1,*, Eva Harris1

1 Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America, 2 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 3 Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua

Abstract

Although heterotypic secondary infection with dengue virus (DENV) is associated with severe disease, the majority of secondary infections are mild or asymptomatic. The mechanisms of antibody-mediated protection are poorly understood. In 2010, 108 DENV3-positive cases were enrolled in a pediatric hospital-based study in Managua, Nicaragua, with 61 primary and 47 secondary infections. We analyzed DENV-specific neutralization titers (NT50), IgM and IgG avidity, and antibody titer in serum samples collected during acute and convalescent phases and 3, 6, and 18 months post-infection. NT50 titers peaked at convalescence and decreased thereafter. IgG avidity to DENV3 significantly increased between convalescent and 3-month time-points in primary DENV infections and between the acute and convalescent phase in secondary DENV infections. While avidity to DENV2, a likely previous infecting serotype, was initially higher than avidity to DENV3 in secondary DENV infections, the opposite relation was observed 3–18 months post-infection. We found significant correlations between IgM avidity and NT50 in acute primary cases and between IgG avidity and NT50 in secondary DENV infections. In summary, our findings indicate that IgM antibodies likely play a role in early control of DENV infections. IgG serum avidity to DENV, analyzed for the first time in longitudinal samples, switches from targeting mainly cross-reactive serotype(s) to the current infecting serotype over time. Finally, serum avidity correlates with neutralization capacity.

Introduction

The four serotypes of the flavivirus dengue virus (DENV1–4) cause the most common mosquito-borne viral disease in humans worldwide, with 30–100 million people infected annually and over 3 billion people at risk [1]. DENV infection can be asymptomatic or cause a spectrum of disease ranging from classical dengue fever (DF) to more severe, life-threatening forms termed dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2]. Approximately 500,000 dengue patients require hospitalization annually, of whom a large proportion are children [3]. Although several antiviral and vaccine candidates are in various phases of preclinical and clinical evaluation, current treatment remains supportive care [4].

The immune response to primary (1st) DENV infection is characterized by an early IgM response followed by an IgG response with predominantly IgG1 and IgG3 subclasses [5]. Naïve B cells are stimulated and develop into DENV-specific B cells, which either differentiate into memory B cells (MBCs) residing in the secondary lymphoid organs or into plasma cells (PCs) secreting antigen-specific antibodies (Abs). Short-lived PCs are active during acute infection, while long-lived PCs (LLPCs) migrate to the bone marrow and are responsible for long-term humoral immunity [6,7]. MBCs, which retain antigen-specific Abs at their surface, and LLPCs, which secrete antigen-specific Abs, undergo affinity maturation, and only clones bearing Abs with the highest affinity survive long-term [8]. This process takes several weeks after acute infection and continues despite the absence of circulating antigen. During a secondary (2nd) DENV infection, MBCs are rapidly activated [9,10]. Prior DENV infection provides robust immunity against the homotypic DENV serotype [11,12]. In contrast, 2nd heterotypic infections are associated with a higher incidence of DHF/DSS, possibly attributable in part to antibody-dependent enhancement (ADE), where pre-formed Abs to the 1st infecting serotype bind but do not neutralize the 2nd infecting serotype, instead facilitating an increase in viral uptake by Fcγ-receptor bearing cells [13]. In addition to ADE, cross-reactive T cells formed during the 1st DENV infection can be over-activated, potentially contributing to dengue pathogenesis [14,15]. However, the vast majority of 2nd DENV infections are asymptomatic or only result in mild disease [16], suggesting a protective immune response [17].
Author Summary

Dengue is the most common mosquito-borne viral illness in humans, with 3 billion people at risk for infection. Four different dengue virus serotypes (DENV1–4) cause the disease, which can be either inapparent or present with flu-like symptoms (Dengue Fever, aka “breakbone fever”). The disease can be more severe and sometimes fatal, with signs of bleeding and vascular leakage leading to shock (Dengue Hemorrhagic Fever/Dengue Shock Syndrome). No specific treatment or vaccine is available. Understanding how the human immune response develops during a natural infection can be beneficial for future vaccine studies and trials. DENV-specific serum neutralizing capacity may play a role in protection. The neutralization capacity of the serum may depend on the serum avidity against DENV, the amount (or titer) of the anti-DENV antibodies, and the accessibility of the epitopes targeted by these antibodies. Here we show that DENV-specific IgM antibodies likely play a role in neutralization during primary DENV infections and show a correlation between serum avidity and neutralization capacity in secondary DENV infections, with greater avidity to a previously infecting DENV serotype as compared to the current infecting DENV serotype in the early phases of infection, switching over time to the opposite situation.

DENV neutralization requires sufficient levels of neutralizing Abs and the number of Abs bound to a single virion to exceed the threshold of enhancement, which depends on antibody avidity and the accessibility of epitopes on the virus particle [18]. The avidity of anti-flavivirus monoclonal Abs (MAbs) was shown to positively correlate with neutralization activity in vitro [19], consistent with lower neutralizing activity observed with MAbs with lower affinity against variant genotypes within a single DENV serotype [20,21]. However, the relation between neutralization activity and polyclonal serum avidity is still unclear [9,22]. Measurement of IgG avidity has been shown to discriminate between 1° and 2° DENV infection in polyclonal serum [23–25] but has not been followed longitudinally.

In this study, we analyzed the DENV-specific neutralization capacity and IgM and IgG avidity to DENV of serum samples from our hospital-based study in Managua, Nicaragua. In Nicaragua, one DENV serotype tends to dominate for several years, while other DENV serotypes co-circulate at lower levels. DENV3 was the dominant serotype in 2008–2011 [26]. Prior to this, DENV2 was the predominant serotype between 1999 and 2002 and between 2005 and 2007 [27–29], while DENV1 predominated between 2002 and 2005 [30]. DENV4 only circulates at a low level in Nicaragua [31]. We studied both 1° and 2° DENV infections from the acute phase until 18 months (m) post-infection. In 2° infections, we measured neutralizing Ab titers and avidity to DENV3, the currently infecting serotype, and to DENV2, the most prevalent previously circulating serotype and our prototype to assess cross-reactive responses and cross-protection [9,28]. As both Ab concentration and avidity can play a significant role in virus neutralization [32], we tested possible correlations between IgM and IgG avidity to DENV, total Ab titer and DENV-specific neutralization titer.

Materials and Methods

Ethics statement

The protocol for this study was reviewed and approved by the Institutional Review Boards (IRB) of the University of California, Berkeley, and the Nicaraguan Ministry of Health. Parents or legal guardians of all subjects provided written informed consent, and subjects 6 years of age and older provided assent.

Study population and laboratory tests

Design and execution of the study, inclusion criteria for the study population, and laboratory tests for confirmation of DENV infection in patients have been previously described [9,33]. Briefly, study enrollment occurred in the Nicaraguan National Pediatric Reference Hospital, Hospital Infantil Manuel de Jesús Rivera (HIMJR), in Managua from August 1, 2010, to January 31, 2011, during the peak dengue season. Inclusion criteria included age between 6 m and 15 years of age. Samples were collected for 3 consecutive days after enrollment (acute), 14–28 days after onset of symptoms (convalescent), and at 3 m, 6 m and 18 m post-illness.

DENV infection was confirmed by reverse transcription–polymerase chain reaction (RT–PCR) amplification of viral RNA [34]; isolation of DENV in C6/36 Aedes albopictus cells [27]; seroconversion of DENV-specific IgM Abs as measured by IgM capture enzyme-linked immunosorbent assay (ELISA) between acute-phase and convalescent-phase serum samples [35]; and/or a ≥4-fold increase in total Ab titer, as measured by Inhibition ELISA [30,36], between paired acute- and convalescent-phase serum samples as previously described [26]. 1° and 2° DENV infections were defined by an Ab titer by Inhibition ELISA of <10 or ≥10 in acute-phase samples, respectively, and/or <2,560 or ≥2,560 in convalescent phase samples, respectively [31,37]. The total Ab titer was measured only during the acute and convalescent phases of the infection, as it decreases substantially thereafter.

Viruses and cell lines

DENV was propagated in Aedes albopictus C6/36 cells as previously described [9]. Cell supernatants were concentrated by centrifugation through Amicon filters (50 kDa, 3,250×g for 20 min at 4°C) or by ultracentrifugation (90,000×g for 2 h at 4°C, Beckman SW28) and resuspended in PBS. DENV2 (strain N172, passage 3) and DENV3 (strain N7236, passage 3) are clinical strains from Nicaraguan patients isolated in the National Virology Laboratory in Managua and passed minimally. Raji-DC-SIGN-R cells (gift from B. Doranz, Integral Molecular, Philadelphia, PA) were grown in RPMI-1640 medium (Invitrogen) with 5% FBS at 37°C in 5% CO2 for use in neutralization assays [30,39].

Neutralization assay

 Serum samples were heat-inactivated at 56°C for 20 min and then diluted in RPMI-1640 with 10% FBS at pH 7.4 using eight 3-fold dilutions (1:10–1:21,650). Neutralization was assessed by flow cytometry using GFP-expressing DENV reporter virus particles (RVPs) as previously described [30,39]. The percent infection for each serum dilution was calculated in relation to the no-serum control. Data were expressed as percent infection versus log10 of the reciprocal serum dilution and fitted to a sigmoidal dose-response curve using GraphPad Prism 5 software (La Jolla, CA) to determine the titer of Ab that achieved a 50% reduction in infection (50% neutralization titer, NT50), which is expressed as the reciprocal of the serum dilution.

Avidity assay

 Serum avidity was measured using a modified ELISA protocol with urea washes [22,23]. DENV3 N7236 was used at a 1:300 dilution (3.4×104 PFU/ml), which yielded an OD of 1.0 using WHO polyclonal serum. To standardize the amount of DENV2
N172 to the amount of DENV3, we used a pan-DENV MAb, 2H12 (gift from G. Screaton, Imperial College, UK) [40]. Serial dilutions of DENV2 and the 1:300 dilution of DENV3 were coated and incubated with 1 µg/mL of 2H12 MAb. The 1:300 dilution of DENV2 (3.6x10⁶ pfu/ml) yielded the same OD as the 1:300 DENV3 and was used thereafter. To determine serum IgG avidity, plates were coated with whole virus and incubated with heat-inactivated diluted serum samples (1:100 in triplicate, then washed with urea or PBS for 10 min before adding the secondary biotin-conjugated Ab (donkey anti-human IgG, 1:1,000, streptavidin-AP conjugate (1:1,000), and PnPP substrate [9]. Using samples from the same study population, we previously optimized the amount of urea to be used, and 6M urea for 1<sup>st</sup> DENV infections and 9M urea for 2<sup>nd</sup> DENV infections yielded the best results for analyzing serum avidity to DENV over time [9]. To measure serum IgM avidity, a donkey anti-human IgM, F<sub>c</sub>-fragment-specific MAb (1:1,000, Jackson ImmunoResearch) was used as secondary Ab. For acute-phase samples, days 4–6 post-onset of symptoms were chosen. Background levels were measured with dengue-negative human sera. For each sample, avidity was calculated as percentage of IgG or IgM bound by dividing the background-adjusted OD after urea washes by the adjusted OD after PBS washes.

Quality control criteria included: background <0.2 OD, WHO polyclonal serum positive control >5X background OD, and WHO positive control of each plate within the mean +/-1 SD of control plate. The control plate was coated with either DENV2 or DENV3 and incubated with WHO polyclonal serum; half the plate was washed with urea (6M or 9M), while the second half was washed with PBS. The mean and SD for the WHO polyclonal positive control was calculated for each urea concentration and each virus as follows:

\[
(mean_{\text{urea}}/mean_{\text{PBS}}) \pm \left( \frac{(\text{SD}_{\text{urea}}/\text{mean}_{\text{area}})^2 + (\text{SD}_{\text{PBS}}/\text{mean}_{\text{PBS}})^2}{2} \right)^{1/2}
\]

Statistical analysis

The data were stratified by 1<sup>st</sup> and 2<sup>nd</sup> infection status for analysis, and gender was evaluated as a possible modifier. Geometric mean total Ab titer, percentage avidity, and NT₅₀ were compared using the two-sided Wilcoxon Signed Rank test to detect differences between the following time-points: acute and convalescent; convalescent and 3 m; 3 m and 6 m; and 6 m and 18 m. Geometric mean Ab titer, avidity, and NT₅₀ were also compared by infection status at each time-point using the Wilcoxon Signed Rank test. Bivariate correlations between NT₅₀ and Ab titer or NT₅₀ and avidity were estimated using the Spearman correlation coefficient at each time-point. To test for differences in avidity, NT₅₀, and Ab titer by clinical signs of dengue severity (vascular leak, hypotensive shock, compensated shock, cutaneous bleeding, hemoconcentration and mucosal bleeding [37]), two-sided Wilcoxon Signed Rank tests were used to compare the geometric mean NT₅₀, total Ab titer and avidity at each time-point, stratifying by immune status. An alpha of p<0.05 was used for statistical significance testing. Calculations were performed in SAS Version 9.2 (The SAS Institute, Cary, NC).

Results

Study participants

Between August 1, 2010, and January 31, 2011, 216 patients were enrolled for suspected dengue at the National Pediatric Reference Hospital, HIJMR. Twelve patients were excluded from analysis: one patient dropped out of the study after enrollment and 11 patients had an undetermined dengue diagnostic result. Of the 204 patients who were followed, 108 patients (52.9%) were laboratory-confirmed as DENV3-positive by RT-PCR and/or virus isolation and were included in this analysis (Table S1). Of these, 61 (36.5%) were 1<sup>st</sup> and 47 (43.5%) were 2<sup>nd</sup> DENV infections (Table 1). Of note, disease severity was relatively low in the 2010–2011 season, with 27 (25.0%) DHF/DSS cases (Table 1) [2]. In the absence of a pre-infection sample, and while we cannot exclude previous DENV1 infections, we hypothesized that most children with 2<sup>nd</sup> DENV infections were previously infected with DENV2, which was the predominant serotype circulating in previous years [28,29]. Thus, we used DENV2 as a representative previously infecting serotype in our analysis.

Longitudinal analysis of DENV-specific serum neutralization

We measured the DENV-specific neutralization capacity of patient sera from 1<sup>st</sup> and 2<sup>nd</sup> DENV3 infections against DENV3, the current infecting serotype, and against DENV2, a representative previously infecting serotype, in 2<sup>nd</sup> infections. Using a flow cytometry-based assay, NT₅₀ was determined at acute, convalescent, 3 m, 6 m, and 18 m time-points (Table S2). The NT₅₀ against DENV3 peaked at convalescence in both 1<sup>st</sup> and 2<sup>nd</sup> cases, with significantly higher titers detected in 2<sup>nd</sup> cases (Figure 1A–B). In 1<sup>st</sup> infections, we observed a significant increase in NT₅₀ from the acute to convalescent phase (p<0.001) followed by a significant drop from convalescence to 3 m post-onset of symptoms (p<0.0001), further decreasing at 6 m (p<0.0001) (Figure 1A). For 2<sup>nd</sup> infections, we noted a similar pattern (p<0.0001 for each pair of adjacent time-points) (Figure 1B). In addition, for 2<sup>nd</sup>

Table 1. Characteristics of patients enrolled in the hospital-based study during the 2010–2011 dengue season in Managua, Nicaragua.

| Indicator | N | % | Mean age ± SD |
|-----------|---|---|---------------|
| Participants | 108 | 100 | 8.4±3.6 |
| Gender | | | |
| Female | 52 | 48.2 | 8.2±3.7 |
| Male | 56 | 51.8 | 8.7±3.7 |
| Disease classification | | | |
| Dengue Fever (DF) | 80 | 74.8 | 8.1±3.6 |
| Dengue Hemorrhagic Fever (DHF) | 25 | 23.4 | 9.1±4.0 |
| Dengue Shock Syndrome (DSS) | 2 | 1.9 | 10.7±0.4 |
| Immune status | | | |
| Primary infection | 61 | 56.5 | 6.9±3.6 |
| Secondary infection | 47 | 43.5 | 10.4±2.8 |
| Clinical sign (proportion with sign present)* | | | |
| Compensated shock | 21 | 19.4 | 8.5±3.5 |
| Hypotensive shock | 6 | 5.6 | 8.4±3.8 |
| Vascular leak | 71 | 65.7 | 7.9±3.8 |
| Cutaneous bleeding | 83 | 77.8 | 8.2±3.6 |
| Mucosal bleeding | 13 | 12.0 | 9.6±3.0 |
| Hemoconcentration | 3 | 2.8 | 9.0±4.7 |

*Defined as in Narvaez et al [32].

doi:10.1371/journal.pntd.0002274.t001
infections, we measured the DENV2-specific neutralization capacity of the serum, which showed a similar trend (Figure 1C).

**Longitudinal analysis of DENV-specific serum avidity**

We measured DENV-specific IgG serum avidity to DENV3 and DENV2 and DENV-specific IgM serum avidity to DENV3 using a modified ELISA with urea washes [22,23]. Avidity was defined as the percentage (%) of IgG or IgM that remained bound after the urea washes. In 1u DENV3 infections, we observed a large increase in IgG serum avidity to DENV3 between convalescence and 3 m post-onset of symptoms (p<0.0001) and a further rise between 5 and 6 months (p = 0.017) and between 6 and 18 months (p = 0.005) post-onset of symptoms (Figure 2A, Table S2). IgM serum avidity to DENV3 in 1u DENV3 acute samples revealed a mean % IgM bound of 47.9 (SD±12.3). In 2u DENV infections, we observed a significant increase in IgG serum avidity to DENV3 between the acute and convalescent phase (p<0.0001), but no further rise at later time-points (Figure 2B, Table S2).

Measuring the avidity of the same 2u infections to DENV2, a likely previously infecting serotype, we observed significantly higher levels of % IgG bound to DENV2 than DENV3 in the acute phase (p=0.0004) (Figure 2C, 3A). However, due to the increase in avidity to DENV3 in the convalescent phase, no significant difference in avidity was detectable between the two serotypes (p = 0.22) (Figure 3B). Subsequently, at the 3 m, 6 m, and 18 m time-points, a shift occurred to significantly higher avidity against DENV3, the currently infecting serotype, than against DENV2 (p<0.0001, p=0.0004, and p=0.001, respectively) (Figure 3C–E). Of note, the IgG serum avidity remained high for 1u DENV cases, while it declined for 2u cases after the convalescent time-point (Figure 2).

**Correlation between DENV-specific total antibody titer, avidity and neutralization capacity of serum**

The ability of serum to neutralize a virus can depend on Ab concentration and/or serum avidity [32], among other parameters. During 1u DENV infections, a positive correlation between IgM serum avidity to DENV3 and DENV3-specific NT50 in the acute phase was observed (Figure 4), suggesting contribution of DENV-specific IgM Abs to early virus neutralization. We also observed a positive correlation between IgG serum avidity to DENV3 and NT50 to DENV3 in the acute phase of 2u DENV3 cases and at the 3 m time-point (Figure 4, Table 2). Due to the slow kinetics of affinity maturation, these highly avid IgG are most likely secreted by pre-existing MBCs, suggesting the contribution of DENV cross-reactive Ab to virus neutralization. Moreover, a correlation was observed between DENV-specific total Ab titers and NT50 against DENV3 and DENV3-specific NT50 in the acute phase of 2u DENV3 infections (Table 2). Interestingly, positive correlations were noted between DENV2-specific NT50 and % IgG bound to DENV2 from the acute phase until 18 m post-infection (Figure S1, Table 2). Lastly, a positive correlation was observed between DENV2-specific NT50 and IgG serum avidity to DENV3 at acute and convalescent time-points (Figure S2, Table 2).

**Association with disease severity and clinical signs of severity**

NT50, total Ab titer, and % IgG bound were compared between patients with and without the following clinical signs, stratified by immune status: compensated shock, hypotensive shock, vascular leak, cutaneous bleeding, mucosal bleeding, and hemoconcentration (defined as in [33]). No difference was observed in the mean NT50, total Ab titer, or % IgG at any time-point examined among patients with and without the following clinical signs.
1° or 2° infections. When using the WHO classification (DF vs. DHF/DSS), patients classified as DF did not demonstrate a statistically significant difference in mean NT₅₀ or % IgG bound compared to those classified as DHF/DSS (stratified by immune status), except for convalescent % IgG bound to DENV3 in 1° DENV3 infections, with 41.2±8.3 for DF and 53.4±14.2 for DHF/DSS (p = 0.005); A significant difference in total Ab titer was observed between 1° DF and DHF/DSS cases at the convalescent time-point (p = 0.035) with a higher Ab titer observed in more severe cases (248.7±79.9 vs. 109.5±30.9).

Discussion

A better understanding of protective immune responses to natural DENV infections is critical for the development of safe and effective vaccines and for defining robust correlates of protection for vaccine trials. Protection from DENV infection and/or disease may depend on DENV-specific serum neutralization and thus may be associated with DENV-specific Ab titer and DENV-specific serum avidity. However, several questions remained unanswered, such as the role of IgM Abs and whether serum avidity correlates with serum neutralization. Using our longitudinal sample series from our hospital-based study, we show for the first time that DENV-specific neutralization titers peak in the convalescent phase and then decrease over time in both 1° and 2° DENV3 infections. We also observed increasing DENV3-specific avidity between the convalescent phase and 3 m post-infection in 1° DENV3 cases and between acute and convalescent phases in 2° DENV3 infections. In addition, we detected higher avidity against a heterologous, potentially previously infecting serotype (DENV2) in the acute phase of 2° DENV3 infections, while avidity was higher against the current infecting serotype at later time-points (3–18 m). Finally, we show for the first time a correlation between serum avidity and serum neutralization titers in the context of DENV infection, and specifically demonstrate that serotype-specific neutralizing titers correlate with serum IgM avidity in 1° acute DENV infections and with serum IgG avidity in 2° DENV infections.

In this study, we show that the DENV-specific NT₅₀ increases from the acute to the convalescent phase in both 1° and 2° infections, with a higher NT₅₀ in 2° cases. Whereas in 1° infections, naïve B cells are stimulated and IgG Abs are detected only in the convalescent phase, cross-reactive memory B cells are reactivated during 2° cases, inducing a rapid increase in DENV-specific IgG Ab in serum [41]. Neutralization is achieved when enough Abs bind to accessible epitopes of DENV, preventing binding to target cells or fusion of the viral and endosomal membranes and subsequent release of viral RNA into the cytoplasm of susceptible cells [42]. At later time-points (3–18 m), a decrease in NT₅₀ was observed, as previously shown with DENV and other viruses [41,43].

In 1° DENV infections, we observed an increase in serum IgG avidity to DENV3 between convalescent phase and 3 m, reflecting affinity maturation of Abs. MBCs and LLPCs develop from naïve B cells and undergo affinity maturation and selection during the first 3 m after infection. As only clones with the highest avidity survive long-term, this leads to a higher mean IgG avidity over time [7,8]. In contrast, in 2° DENV infections, we observed an increase in serum IgG avidity to DENV3 earlier, between the acute and convalescent phase, which cannot be explained by affinity maturation of newly activated DENV3-specific B cells. Rather, this suggests that cross-reactive Abs secreted by pre-existing MBCs contribute to the early increase in avidity during 2° heterotypic DENV infections.
In previous studies, we found significantly higher serum IgG avidity directed to a possible previously infecting DENV serotype (DENV2) as opposed to the current infecting serotype (DENV3) in the acute phase of 2\textsuperscript{nd} DENV3 infections [9]. Here, we confirm these findings and show that subsequently, serum IgG avidity against the current infecting serotype increases over time such that avidity to the current infecting serotype is greater than that to the previous infecting serotype 3–18 m post-infection. Serum IgG avidity to DENV2 decreases at 18 m time-point, possibly as DENV2-specific LLPCs are displaced from the bone marrow and replaced by newly generated DENV3-specific LLPCs. LLPC niches are limited in the bone marrow, and newly formed LLPCs can replace LLPCs formed during earlier infections [44,45]. The decrease in serum IgG avidity to DENV3 at the 18 m time-point could be explained by a strong extra-follicular response induced by the presence of pre-existing anti-DENV Abs in 2\textsuperscript{nd} infections, inhibiting the germinal center response and thus inhibiting a strong long-term immunity to the current infecting serotype, DENV3 [46].

Correlation between serum avidity and serum neutralization has been reported for measles, HIV and cytomegalovirus infections [47–49]. We analyzed here whether DENV-specific serum avidity and total Ab titer correlate with DENV-specific neutralization. During 1\textsuperscript{st} DENV infections, neither IgG serum avidity to DENV3 nor DENV-specific total Ab titer correlated with DENV3-specific NT\textsubscript{50}. Rather, the NT\textsubscript{50} correlated with IgM serum avidity to DENV3 in the acute phase of 1\textsuperscript{st} DENV3 infections, showing that highly avid IgM Abs are also highly neutralizing and suggesting that IgM Abs play an important role in DENV-specific serum neutralization. In contrast, in the acute phase of 2\textsuperscript{nd} DENV infections, DENV3-specific NT\textsubscript{50} correlated with IgG serum avidity to DENV3. Because of the rapid kinetics of appearance of IgG Abs in a 2\textsuperscript{nd} DENV infection and the slow affinity maturation process, these highly avid IgG Abs are most likely secreted by MBCs formed during the previous infection rather than by newly-activated naive B cells. This suggests that cross-reactive Abs contribute to neutralization of acute 2\textsuperscript{nd} DENV infections. This is consistent with the isolation of strongly neutralizing cross-reactive MAbs from 2\textsuperscript{nd} DENV infections (S. Smith, J. Crowe, R. de Alwis, A. de Silva & E. Harris, unpublished data). IgG serum avidity to DENV2 and DENV2-specific NT\textsubscript{50} correlated at all time-points, suggesting that affinity maturation after the 1\textsuperscript{st} infection contributes to strengthening the neutralizing activity of serum Abs. We also observed a correlation between IgG serum avidity to DENV3 and DENV2-specific NT\textsubscript{50}, further supporting the relation between cross-reactive Abs and neutralization. Furthermore, a positive correlation between DENV-specific total Ab titer and DENV3-specific NT\textsubscript{50} in acute 2\textsuperscript{nd}
DENV infections was found, showing that a greater amount of Abs correlates with neutralization activity. Since dengue disease severity may be associated with sub-neutralizing [enhancing] concentrations of DENV-specific Abs [50,51], we analyzed NT50 titers and IgG serum avidity among DF vs. DHF/DSS patients and among cases with different clinical signs of severity but did not find many significant differences.

However, this could be due to the relatively low disease severity in the 2010–2011 epidemic in Nicaragua and thus the small sample size of DHF/DSS. Finally, pre-infection samples are not available through this hospital-based study; thus, we chose one likely previous infecting serotype (DENV2) to analyze in this group of patients. Analysis of samples collected from documented sequential infections in our long-term prospective dengue cohort study will enable more precise investigation of cross-reactive Abs in 2nd DENV infections.

Overall, this study showed that IgM and cross-reactive IgG contribute to neutralization during acute DENV infections. To further support these results, we are conducting additional analyses of the DENV-specific serum neutralization capacity, including: 1) the use of β-mercaptoethanol to chemically deplete IgM Abs and 2) the use of DENV virions to deplete heterologous serotype cross-reactive Abs. While cross-reactive serum avidity dominates the acute 2nd DENV response, avidity to the current infecting serotype becomes dominant over time. Significant correlations were observed between neutralizing Ab titers and serum avidity to both the current and a heterotypic serotype. Future studies will address the relation of avidity and NT50 to infection outcome (symptomatic vs. inapparent) and to disease severity. The unexpected results from the first proof-of-concept dengue live attenuated vaccine efficacy trial (Phase 2b) that were recently published [52] highlight the critical need to better understand the immune response to natural DENV infections and vaccine candidates and to identify robust correlates of protection. We believe that measurement of DENV-specific serum avidity should be integrated into evaluation of future vaccine trials and applied more broadly to the study of the immune response to DENV after natural infections.

Supporting Information

Figure S1 Correlation between DENV2-specific NT50 and IgG avidity to DENV2 at all time-points of 2nd DENV3 infections. Spearman's rank correlation coefficient (ρ) and p-value were calculated between the pairs of NT50 and % IgG bound.

(DOCX)

Figure S2 Correlation between DENV2-specific NT50 and IgG avidity to DENV3 at acute and convalescent time-points of 2nd DENV3 infections. Spearman's rank correlation coefficient (ρ) and p-value were calculated between the pairs of NT50 and % IgG bound.

(DOCX)

Table S1 Laboratory confirmation of DENV infection.

(DOCX)

Table S2 Summary of NT50, Ab titer and avidity to DENV3 and DENV2, respectively, by time-point and immune status.

(DOCX)

Author Contributions

Conceived and designed the experiments: AP SZ EH. Performed the experiments: AP LL. Analyzed the data: AP LL EAC SZ. Contributed reagents/materials/analysis tools: AB EH. Wrote the paper: AP LL EAC SZ EH.

References

1. Simmons CP, Farrar JJ, Nguyen vV, Wills B (2012) Dengue. N Engl J Med 366: 1423–1432.
2. WHO (1997) Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. Geneva.

Table 2. Spearman's correlation of NT50 and % IgG bound or Ab titer stratified by immune status.

| Time-point          | N* | Coefficient | p-value |
|---------------------|----|-------------|---------|
| Primary DENV3 % IgG bound vs. DENV3 NT50 |    |             |         |
| Acute               | -  | -           | -       |
| Convalescent        | 48 | 0.24        | 0.095   |
| 3 month             | 48 | 0.07        | 0.65    |
| 6 month             | 44 | -0.05       | 0.074   |
| 18 month            | 30 | 0.11        | 0.57    |
| Secondary DENV3 % IgG bound vs. DENV3 NT50 |    |             |         |
| Acute               | 39 | 0.49        | 0.0016  |
| Convalescent        | 32 | -0.08       | 0.66    |
| 3 month             | 44 | 0.45        | 0.003   |
| 6 month             | 44 | 0.23        | 0.13    |
| 18 month            | 37 | 0.13        | 0.43    |
| Secondary DENV2 % IgG bound vs. DENV2 NT50 |    |             |         |
| Acute               | 36 | 0.44        | 0.007   |
| Convalescent        | 31 | 0.44        | 0.013   |
| 3 month             | 44 | 0.42        | 0.004   |
| 6 month             | 44 | 0.57        | <0.0001 |
| 18 month            | 38 | 0.41        | 0.01    |
| Secondary DENV2 % IgG bound vs. DENV3 NT50 |    |             |         |
| Acute               | 35 | 0.09        | 0.62    |
| Convalescent        | 32 | 0.08        | 0.66    |
| 3 month             | 44 | 0.24        | 0.12    |
| 6 month             | 44 | 0.08        | 0.61    |
| 18 month            | 38 | 0.03        | 0.87    |
| Secondary DENV3 % IgG bound vs. DENV2 NT50 |    |             |         |
| Acute               | 40 | 0.56        | 0.0002  |
| Convalescent        | 31 | 0.47        | 0.0073  |
| 3 month             | 44 | 0.04        | 0.8     |
| 6 month             | 44 | 0.16        | 0.31    |
| 18 month            | 37 | -0.18       | 0.29    |
| Primary total DENV-specific Ab titer vs. DENV3 NT50 |    |             |         |
| Acute               | 42 | -0.019      | 0.90    |
| Convalescent        | 47 | 0.065       | 0.66    |
| Secondary total DENV-specific Ab titer vs. DENV3 NT50 |    |             |         |
| Acute               | 39 | 0.61        | <0.0001 |
| Convalescent        | 32 | 0.32        | 0.075   |

*Number of subjects with paired NT50, avidity, or Ab titer data for calculation of Spearman's coefficient.

doi:10.1371/journal.pntd.0002274.t002
28. OhAinle M, Balmaseda A, Macalalad AR, Tellez Y, Zody MC, et al. (2011)
27. Balmaseda A, Sandoval E, Perez L, Gutierrez CM, Harris E (1999) Application
26. Gutierrez G, Standish K, Narvaez F, Perez MA, Saborio S, et al. (2011) Unusual
25. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, et al. (2005)
23. de Souza VA, Fernandes S, Araujo ES, Tateno AF, Oliveira OM, et al. (2004)
22. Zompi S, Santich BH, Beatty PR, Harris E (2012) Protection from secondary
21. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, et al.
20. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, et al. (2010)
17. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, et al. (2002) Effect
16. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev
15. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangth-
14. Mangada MM, Rothman AL (2005) Altered cytokine responses of dengue-
13. Smith KG, Light A, Nossal GJ, Tarlinton DM (1997) The extent of affinity
12. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E (2012) Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 6: e1568.
11. Sabin AB (1952) Research on dengue during World War II. Am J Trop Med Hyg 1: 30–56.
10. Endy TP, Nisalak A, Chunsuwanitwat S, Vaughn DW, Green S, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189: 980–1000.
9. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421–467.
8. Smith KG, Light A, Nossal GJ, Tarlinton DM (1997) The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J 16: 2996–3006.
7. McHeyzer-Williams LJ, McHeyzer-Williams MG (2005) Antigen-specific memory B cell development. Annu Rev Immunol 23: 487–513.
6. Amanna IJ, Slifka MK (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236: 125–138.
5. Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587–619.
4. Durbin AP, Whitehead SS (2010) Dengue vaccine candidates in development. Curr Top Microbiol Immunol 338: 129–143.
3. Gibbons RV, Vaughan DW (2002) Dengue: an escalating problem. BMJ 324: 1563–1566.
2. Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587–619.
1. Amanna IJ, Sflita MK (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236: 125–138.